SARS Conference

International Conference on SARS
one year after the (first) outbreak
May 8-11 2004
Lübeck Germany

The Movies can be viewed with Quicktime

Saturday, May 08, 2004

Opening Ceremony
Moderator: Rolf Hilgenfeld, Lübeck

U. Erdsiek-Rave, Minister of Education, Science, Research and Culture of Schleswig-Holstein, Kiel, Germany
A.-X. Trautwein, Rector of the University of Lübeck, Lübeck, Germany
B. Saxe, Mayor of the Hanseatic City of Lübeck, Lübeck, Germany

Session IA: SARS and Public Health Policies
Chair: Hans-Dieter Klenk, Germany

S. Mardel, WHO, Geneva. Switzerland
The WHO response to SARS: Past, present, and future

B. Singh, Canadian Institutes of Health Research and University of Western Ontario, London, Ontario, Canada
SARS in Canada: Initial responses and long-term plans

A. Dyke, North York Hospital, Toronto, Ontario, Canada
Lessons learned from a SARS story

D. Koh, National University of Singapore, Singapore
Impact of severe acute respiratory syndrome on health-care workers in Singapore

Z.-H. Deng, Center for Disease Control and Prevention of Guangdong Province, Guangzhou, China
SARS lessons learnt and public health in the future

V. Puro, National Institute for Infectious Diseases, Rome, Italy
Feasibility of WHO SARS alert in the post-outbreak period in low-risk areas

Session IIA: Epidemiology
Chair: Hualiang Jiang, Shanghai

G. Zhao, Chinese National Human Genome Center, Shanghai, China
Molecular evolution of the SARS coronavirus

Session IIIA: Vaccines
Chair: Bruno Canard, Marseille

L. Enjuanes, Centro Nacional de Biotecnologia, Madrid, Spain
Coronavirus reverse genetics and vaccine development

Parallel session IIIB: Vaccines
Chair: Luis Enjuanes, Madrid

J. Cao, Canadian Science Centre for Human and Animal Health, Winnipeg, MB, Canada
Evaluation of safety and efficacy of modified vaccinia virus Ankara-based recombinant SARS vaccine in ferrets

S.-M. Ngai, The Chinese University of Hong Kong, Hong Kong
Synthetic peptide studies on the SARS coronavirus spike glycoprotein: Perspective for SARS vaccine development
(Talk will be given by L.W. Stanton, Hong Kong)

P. Roy, London of School of Hygiene and Tropical Medicine, London, UK
Expression of SARS protein and assembly of virus-like particles

Sunday, May 09, 2004

Session IV: Genomics and Bioinformatics
Chair: Leo Poon, Hong Kong

J. Wang, Beijing Genomics Institute, Beijing, China
Genomic features and diagnosis of SARS-associated coronavirus

V. Vega, Genome Institute of Singapore, Singapore
Mutational dynamics of the SARS coronavirus in cell culture and human populations

C. Wong, Genome of Institute of Singapore, Singapore
Tracking the genetic diversity of the SARS coronavirus using high-throughput full-genome re-sequencing arrays

V. Aristov, National Medical University of O.O. Bohomoletz. Ukraine
Prediction of the three-dimensional structure of the 3'UTR of SARS-CoV RNA

Session V: Origin of SARS
Chair: Bhagirath Singh, London, Ontario, Canada

L. Poon, The University of Hong Kong, Hong Kong
Detection of SARS-CoV in animals and humans

L. Lin, Center of Disease Control of Guangdong Province, Guangzhou, China
Investigation of rodent infestation and the SARS-CoV genes in rats around living environment of the initial SARS case in 2004

L. Vijgen, University of Leuven, Leuven, Belgium
Molecular clock analysis of bovine coronaviruses and human coronavirus OC43 suggests a relatively recent zoonotic transmission event

Session VIA: Molecular biology
Chair: Jing Wang, Beijing

E.J. Snijder, Leiden University Medical Center, Leiden, The Netherlands
The Nidovirus connection: RNA synthesis in Coronaviruses and Arteriviruses

B. Sun, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China
Characterization of the 3A protein of SARS-associated coronavirus in infected Vero E6 cells and SARS patients

Parallel session VIb: Molecular biology
Chair: Eric Snijder, Leiden

M. Eickmann, University of Marburg, Marburg, Germany
Maturation and proteolytic processing of severe acute respiratory syndrome (SARS)-associated coronavirus spike protein

I.M. Jones, University of Reading, Reading, UK
Expression, characterization and antibody binding of the SARS-CoV spike protein

S. Shen, Institute of Molecular and Cell Biology, Singapore
Expression, processing, and maturation of the spike (S) protein of the severe acute respiratory coronavirus (CoV)

Session VII: Newly emerging viruses
Chair: Heinz Feldmann, Winnipeg

L. van der Hoek, University of Amsterdam, Amsterdam, The Netherlands
Identification of a new human coronavirus

G. Kwik, Center for Biosecurity of the University of Pittsburgh Medical Center, Baltimore, MD, U.S.A.
SARS: A case study for biodefense

H.-D. Klenk, University of Marburg, Marburg, Germany
Determinants of influenza pathogenesis in birds and mammals

Round-table discussion on newly emerging infectious diseases
Chairperson: H.-D. Klenk

Monday, May 10, 2004

Session VIC: Molecular biology
Chair: Hyeryun Choe, Boston

J. Ziebuhr, University of Würzburg, Würzburg, Germany
Identification and characterization of coronavirus replicase gene-encoded ADP ribose 1'-phosphatase and sequence-specific endoribonuclease activities

Session IXA: Drug Discovery
Chair: Zihe Rao, Beijing

W. Doerr, University of Frankfurt, Frankfurt, Germany
Search for SARS therapy

Parallel session IXB: Drug Discovery
Chair: Wolfgang Doerr, Frankfurt

B.J. Bosch, Utrecht University, Utrecht, The Netherlands
SARS-CoV infection inhibition using spike protein heptad repeat-derived peptides

E. Keyaerts, University of Leuven, Leuven, Belgium
In-vitro activity of S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound against SARS coronavirus replication

L. Stanton, Genome Institute of Singapore, Singapore
Inhibition of SARS coronavirus infection in vitro with clinically approved antiviraldrugs

Parallel session VID: Molecular biology
Chair: John Ziebuhr, Würzburg

S. Tong, Centers for Disease Control and Prevention, Atlanta, GA, U.S.A.
Limited variation in SARS coronavirus S and N protein genes observed by direct sequencing from patients' orginal clinical specimens

E. Vicenzi, AIDS Immunopathogenesis Unit, Milan, Italy
Biological and molecular characterization of the SARS coronavirus HSR1 isolate

Session IXC. Drug Discovery
Chair: David Kelvin, Toronto

H. Jiang, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, China
Discovering anti-SARS drugs targeting 3CL-proteinase and N protein

Session X. Animal models
Chair: Hong-kui Deng, Beijing

A.D.M.E. Osterhaus, Utrecht University, Utrecht, The Netherlands
SARS in ferrets and cats - part1
/ - part2

D. Wu, Harbin Veterinary Research Institute, Chinese Academy of Science, Harbin, China
Civets are susceptile to infection by SARS coronavirus

Parallel Session XI: Structural biology
Chair: Rolf Hilgenfeld, Lübeck

B. Canard, University of Marseille, Marseille, France
Progress in the structural and functional characterization of the coronavirus replicase complex: Crystal structure of the SARS-CoV nsp9

Z. Rao, Tsinghua University and Institute of Biophysics, Chinese Academy of Science, Beijing, China
Structural Genomics study of the SARS coronavirus - the crystal structures of SARS virus main protease (Mpro) and its complex with an inhibitor

L. Rychlewski, BioInfoBank Institute, Poznan, Poland
3D-Jury: A simple protein structure Meta-Predictor and its application for structural annotations of the SARS proteins

Tuesday, May 11, 2004

Session XIIA: Virus-host interactions and immunology
Chair: Verena Gauss-Müller, Lübeck

H. Choe, Harvard Medical School, Boston, MA, U.S.A.
SARS-CoV receptor

H. Deng, Peking University, Beijing, China
Identification of cell surface receptor and analysis of cell tropism for SARS coronavirus

P.C.-S. Chong, National Yang-ming University, Taipei, Taiwan
Identification of the receptors and their respective binding-domains of SARS coronavirus spike protein

Session XIIB: Virus-host interactions and immunology
Chair: Matthias Niedrig, Berlin

S. Pöhlmann, University of Erlangen-Nürnberg, Erlangen, Germany
The S protein of severe acute respiratory syndrome (SARS)-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients

M.R. Capobianchi, National Institute of Infectious Diseases, Rome, Italy
Protective role of bcl-2 in the induction of cytopathic effect and of apoptotic cell death in SARS-CoV-infected Vero cells, in the absence of inhibition of viral replication